Results

587.

Buttgereit, T., Vera, C., Aykanat, S., Weller, K., Gutsche, A., Maurer, M.⁺, and Magerl, M.: The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center. Front. Immunol. 2024: 15; 1405317. IF: TBD (IF 2023: 5.70)

588.

Moon, S., Stasikowska-Kanicka, O., Wagrowska-Danilewicz, M., Hawro, M., Metz, M., Maurer, M., and Hawro, T.⁺: Clinically uninvolved but not healthy – the skin of patients with atopic dermatitis is primed for itch and inflammation. J. Eur. Acad. Dermatol. Venereol. 2024: 38; 1089-1100. IF: TBD (IF 2023: 8.40)

589.

Cherrez-Ojeda, I.⁺, Bousquet, J., Giménez-Arnau, A., Godse, K., Krasowska, D., Bartosińska, J., Szczepanik-Kułak, P., Wawrzycki, B., Kolkhir, P., Allenova, A., Allenov A, Tkachenko S, Teovska Mitrevska N, Mijakoski D, Stoleski S, Kolacinska-Flont, M., Kuprys-Lipinska, I., Molinska, J., Kasperska-Zając, A., Zajac, M., Zamlynski, M., Mihaltan, F., Ulmeanu, R., Zalewska-Janowska, A., Tomaszewska, K., Al-Ahmad, M., Al-Nesf, M. A., Ibrahim, T., Aqel, S., Pesqué, D., Rodríguez-González, M., Wakida-Kuzunoki, G. H., Ramon, G. D., Ramon, G. N., Neisinger, S., Bonnekoh, H., Rukhadze, M., Khoshkhui, M., Fomina, D., Larenas-Linnemann, D., Košnik, M., Oztas Kara, R., Caballero López, C. G., Liu, Q., Ivancevich Juan, C., Ensina, L. F., Rosario, N., Kvedariene, V., Ben-Shoshan, M., Criado, R. F. J., Bauer, A., Cherrez, A., Chong-Neto, H., Rojo-Gutierrez, M. I., Rudenko, M., Larco Sousa, J. I., Lesiak, A., Matos, E., Muñoz, N., Tinoco, I., Moreno, J., Crespo Shijin, C., Hinostroza Logroño, R., Sagñay, J. C., Faytong-Haro, M., Robles-Velasco, K., Zuberbier, T., and Maurer, M.⁺: Patient-reported outcome measures in atopic dermatitis and chronic urticaria are underused in clinical practice. J. Allergy Clin. Immunol. Pract. 2024: 12; 1575-1583. IF: TBD (IF 2023: 8.20)

590.

Zhang, D. G.⁺, Sørensen, J. A., Pedersen, N. H., Ali, Z., Kocatürk, E., Maurer, M., and Thomsen, S. F.: Online depiction of urticaria is often flawed and does not reflect the spectrum of clinical manifestation. Dermatology 2024: 240; 507-513. IF: TBD (IF 2023: 3.00)

591.

Petersen, R. S., Fijen, L. M., Apfelbacher, C., Magerl, M., Weller, K., Aberer, W., Adatia, A., Audhya, P., Bara, N. A., Betschel, S., Boccon-Gibod, I., Bouillet, L., Brodszki, N., Busse, P. J., Buttgereit, T., Bygum, A., Cancian, M., Craig, T., Csuka, D., Farkas, H., Fomina, D., Gil-Serrano, J., Gompels, M., Fogelbach, G. G., Guilarte, M., Hide, M., Kiani-Alikhan, S., Kinaciyan, T., Lenten, A., Lleonart, R., Longhurst, H., Lumry, W. R., Malbran, A., Malinauskiene, L., Matta Campos, J. J., Mendivil, J., Nieto-Martinez, S. A., Peter, J. G., Porebski, G., Reshef, A., Riedl, M., Valerieva, A., Waserman, S., Maurer, M., and Cohn, D. M.⁺: A core outcome set for efficacy of acute treatment of hereditary angioedema. J. Allergy Clin. Immunol. Pract. 2024: 12; 1614-1621. IF: TBD (IF 2023: 8.20)

592.

Grekowitz, E., Metz, M., Altrichter, S., Bauer, A., Brockow, K., Heine, G., Lionnet, L., Kaplan Saday, K., Hultsch, T., Soerensen, O., and Maurer, M.⁺: Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase 2a, randomised, double-blind, placebo-controlled, multicentre, crossover trial. Br. J. Dermatol. 2024: 190; 825-835. IF: TBD (IF 2023: 11.00)

593.

Ali, Z.⁺, Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Allerup, J. A. C., Maurer, M., Kocatürk, E., Vestergaard, C., and Thomsen, S. F.: Smartphone photographs of chronic urticaria taken by patients are of good quality and useful in the clinic. Dermatology 2024: 240; 357-361. IF: TBD (IF 2023: 3.00)

498.

Buttgereit, T.⁺, Pfeiffenberger, M., Frischbutter, S., Krauß, P. L., Chen, Y., Maurer, M., Buttgereit, F., and Gaber, T.: Inhibition of complex I of the respiratory chain, but not complex III, attenuates degranulation and cytokine secretion in human skin mast cells. Int. J. Mol. Sci. 2022: 23; 11591. IF: 5.60